"This analysis explores the critical shifts in the sector, highlighting a projected growth trajectory driven by technological integration and changing consumer dynamics."

According to analysts at Vantage Market Research, the United States Drug Discovery Market size was worth USD 31.84 billion in 2025 and is projected to reach USD 63.79 billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 7.20% from 2026 to 2035. Key trends include artificial intelligence and machine learning-enabled drug discovery, high-throughput screening, precision medicine, genomics and proteomics, computational drug design, CRISPR and gene editing, laboratory automation, cloud-based research platforms, collaborative discovery models, and increasing use of outsourced research services.

United States Drug Discovery Market Overview

The United States Drug Discovery Market forms the foundation of pharmaceutical innovation by supporting the identification, validation, optimization, and advancement of therapeutic candidates across diverse disease areas. The United States maintains a mature biomedical research ecosystem supported by pharmaceutical companies, biotechnology innovators, academic institutions, contract research organizations, venture capital firms, and specialized technology providers. This interconnected environment supports the translation of scientific discoveries into commercially viable therapeutic candidates while sustaining investment in advanced research infrastructure.

Growing pharmaceutical R&D expenditure, expansion of biotechnology enterprises, and increasing emphasis on precision medicine are supporting demand for sophisticated drug discovery capabilities. Organizations are increasingly integrating artificial intelligence, machine learning, computational chemistry, genomics, bioinformatics, and laboratory automation into research workflows to improve candidate identification and portfolio decision-making. High-throughput screening remains an important component of discovery operations, while digital technologies are expanding the role of predictive analytics and computational modeling across early-stage research.

The expansion of outsourced discovery services is also reshaping procurement strategies across the pharmaceutical and biotechnology industries. Contract research organizations provide specialized scientific expertise, advanced laboratory infrastructure, flexible capacity, and integrated discovery services, enabling pharmaceutical companies to combine internal research capabilities with external expertise. Collaborative research partnerships involving pharmaceutical companies, biotechnology firms, academic institutions, technology providers, and research organizations are further strengthening access to specialized technologies and scientific knowledge.

Precision medicine is creating additional demand for genomic profiling, biomarker identification, molecular diagnostics, and data-intensive research platforms. Drug developers increasingly incorporate disease-specific molecular information into target identification and candidate selection processes, supporting the development of more targeted therapeutic approaches. Regulatory infrastructure, intellectual property protection, scientific talent, and established research institutions further reinforce the commercial environment for drug discovery across the United States.

Artificial intelligence is emerging as a major technology theme across the market, with companies deploying machine learning, generative AI, predictive modeling, and computational platforms to support molecular design and candidate prioritization. In January 2026, Eli Lilly and NVIDIA announced a co-innovation AI lab focused on drug discovery, with the companies planning to invest up to USD 1 billion over five years in talent, infrastructure, and compute.

Overall, the US Drug Discovery Market is positioned for continued expansion as pharmaceutical and biotechnology organizations increase investments in advanced research technologies, precision medicine, automation, computational discovery, and flexible external research models.

Eli Lilly and NVIDIA Announced AI Co-Innovation Lab for Drug Discovery

January 2026 — Eli Lilly and NVIDIA announced a co-innovation AI lab focused on applying artificial intelligence and accelerated computing to drug discovery. The companies announced plans to invest up to USD 1 billion over five years in talent, infrastructure, and compute, with the initiative focused on connecting computational research with laboratory experimentation.

Key Takeaways from the Report

Small molecule drugs accounted for the dominant revenue contribution due to established development pathways, manufacturing scalability, and broad therapeutic applications.
Artificial intelligence and machine learning represent the fastest-expanding technology category as pharmaceutical organizations integrate predictive models, computational analysis, and automated research workflows.
Oncology remained the leading therapeutic area, supported by sustained investment in targeted therapies, immuno-oncology, antibody-drug conjugates, and precision medicine.
Pharmaceutical companies represented the largest end-user category through extensive internal research infrastructure, diversified pipelines, and strategic partnerships.
Outsourced discovery services recorded the strongest commercial expansion as organizations increasingly access specialized scientific expertise and advanced research infrastructure through contract research organizations.
Procurement strategies increasingly prioritize integrated digital discovery platforms, laboratory automation, data interoperability, cybersecurity, scalability, and lifecycle support.
Genomics, proteomics, CRISPR-based research, bioinformatics, and computational drug discovery are strengthening the integration between laboratory experimentation and digital research environments.
Strategic collaborations between pharmaceutical companies, biotechnology firms, academic institutions, technology providers, and contract research organizations are expanding access to advanced discovery capabilities.

Top Players

Pfizer Inc.
Merck & Co., Inc.
Johnson & Johnson
Bristol Myers Squibb
Eli Lilly and Company
Amgen Inc.
Gilead Sciences, Inc.
AbbVie Inc.
Thermo Fisher Scientific Inc.
Charles River Laboratories
IQVIA
Labcorp
Recursion Pharmaceuticals
Schrödinger, Inc.

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine the US market landscape, and evaluate the impact of major industry developments on pharmaceutical research and innovation. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, procurement intelligence, value chain analysis, and strategic assessment of major participants, providing actionable intelligence to support business and investment decisions.

Latest Announcement

July 2026 — Schrödinger, Inc. introduced the early-access version of Bunsen, an agentic AI co-scientist designed to help researchers interpret scientific objectives, develop computational strategies, execute molecular discovery workflows, and analyze results. The platform combines AI with physics-based simulation to support computational drug discovery and research decision-making.